The retrospective analysis also shows that, as in the present study, HER2-low-positive, HR-negative patients are underrepresented, even though they are an interesting cohort for further treatment strategies, like endocrine-refractory, HR-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.